Background Resistance to immune checkpoint inhibitors (ICIs) has been linked to local
immunosuppression independent of major ICI targets (eg, PD-1). Clinical experience with …

The emergence of immunotherapy has dramatically changed how non–small cell lung
cancer is treated, and longer survival is now possible for some patients, even those with …

Immune checkpoint inhibitor (ICI) therapies, including the programmed cell death protein 1
(PD-1) axis blockade, are considered a major oncological breakthrough of the early twenty …

Inhibitors of the programmed cell death 1 (PD-1) pathway show the potential to substantially
increase the efficacy of therapy for various malignancies, including non–small cell lung …

Immune checkpoint inhibition with anti-PD-1 therapy has been notably successful in non-
small cell lung cancer (NSCLC) and changed standard practice in multiple settings …

Objectives Treatment of non-small cell lung cancer (NSCLC) with immune checkpoint
blockade (ICB) has resulted in striking clinical responses, but only in a subset of patients …

Background Immune checkpoint inhibitors (ICIs) have shown unprecedented clinical benefit
in cancer immunotherapy and are rapidly transforming the practice of advanced lung cancer …

Purpose: We sought to identify features of patients with advanced non–small cell lung
cancer (NSCLC) who achieve long-term response (LTR) to immune checkpoint inhibitors …

Cancer immunotherapy with immune checkpoint inhibitors (ICIs) has become a “game
changer” in the treatment of advanced non-small cell lung cancer (NSCLC). Its most …

Therapies targeting immune checkpoints have recently shown encouraging activity in
patients with heavily pretreated advanced non–small cell lung cancer (NSCLC) …